We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · October 29, 2020

Neoadjuvant Paclitaxel/Olaparib vs Paclitaxel/Carboplatinum in Patients With HER2-Negative Breast Cancer and Homologous Recombination Deficiency

Annals of Oncology

 

Additional Info

Annals of Oncology
Neoadjuvant Paclitaxel/Olaparib In Comparison to Paclitaxel/Carboplatinum in Patients With HER2-Negative Breast Cancer and Homologous Recombination Deficiency (GeparOLA Study)
Ann. Oncol 2020 Oct 21;[EPub Ahead of Print], PA Fasching, T Link, J Hauke, F Seither, C Jackisch, P Klare, S Schmatloch, C Hanusch, J Huober, A Stefek, S Seiler, WD Schmitt, C Uleer, G Doering, K Rhiem, A Schneeweiss, K Engels, C Denkert, RK Schmutzler, E Hahnen, M Untch, N Burchardi, JU Blohmer, S Loibl

Further Reading